Pan Shi-Yin, Wang Yang-Zheng, Li Jun, Zhang Xue-Hui, Wang Jin, Zhu Xiu-Ping, Xiao Xiang-Hua, Liu Jun-Tian
Department of Pharmacology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an 710061, Shaanxi Pronvince, China.
Shaanxi Provincial Clinical Research Center for Ophthalmology, Xi'an First Hospital, Xi'an 710002, Shaanxi Province, China.
Int J Ophthalmol. 2022 Jul 18;15(7):1122-1127. doi: 10.18240/ijo.2022.07.12. eCollection 2022.
To investigate the effect of 0.01% atropine sulphate eye gel on myopia progression and axial elongation in a 6-month treatment in children.
Totally 185 children aged 6-12y with binocular myopia of 3.0 D or less in both eyes were enrolled in this prospective cohort study. The atropine group (=125) received one drop of 0.01% atropine sulphate eye gel in each eye before bedtime daily. The control group included 60 matched children without drug intervention during the same period. The spherical equivalent and axial length was recorded at baseline and the sixth month of treatment. The efficacy was evaluated by the change of the spherical equivalent and axial length. Adverse events were also recorded.
The average spherical equivalent and axial length at baseline were not statistically significant between the atropine group (-1.64±0.80 D, 24.13±0.76 mm) and the control group (-1.59±0.94 D, 24.06±0.77 mm, >0.05). After 6mo, there was significantly difference in the spherical equivalent progression between the atropine and the control group (-0.27±0.33 -0.60±0.35 D, <0.001), with a relative reduction of 55.0% in myopia progression. The increase in axial elongation in the atropine group was significantly less than control group (0.19±0.14 0.26±0.14 mm, <0.001), with a relative reduction of 26.9% in axial length. The 84.4% and 38.4% of the eyes progressed by less than 0.50 D and remained stable in the atropine group, compared with 51.7% and 4.2% in the control group. No adverse events were observed.
Atropine sulphate eye gel 0.01% can slow down myopia progression and axial elongation in children with a 6-month treatment.
探讨0.01%硫酸阿托品眼凝胶对儿童进行6个月治疗后近视进展和眼轴伸长的影响。
本前瞻性队列研究纳入了185名6至12岁双眼近视度数均在3.0 D及以下的儿童。阿托品组（n = 125）每天睡前在每只眼中滴入一滴0.01%硫酸阿托品眼凝胶。对照组包括60名匹配的儿童，在同一时期不进行药物干预。在基线和治疗的第六个月记录等效球镜度和眼轴长度。通过等效球镜度和眼轴长度的变化评估疗效。同时记录不良事件。
阿托品组（-1.64±0.80 D，24.13±0.76 mm）和对照组（-1.59±0.94 D，24.06±0.77 mm，P>0.05）在基线时的平均等效球镜度和眼轴长度无统计学差异。6个月后，阿托品组和对照组在等效球镜度进展方面存在显著差异（-0.27±0.33 D对-0.60±0.35 D，P<0.001），近视进展相对降低了55.0%。阿托品组眼轴伸长的增加明显小于对照组（0.19±0.14 mm对0.26±0.14 mm，P<0.001），眼轴长度相对减少了26.9%。阿托品组中84.4%的眼睛进展小于0.50 D并保持稳定，而对照组分别为51.7%和4.2%。未观察到不良事件。
0.01%硫酸阿托品眼凝胶对儿童进行6个月治疗可减缓近视进展和眼轴伸长。
